Belimumab (Benlysta ®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE).

Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS).

2020年9月16日 · In a phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 104-week trial conducted at 107 sites in 21 countries, we assigned adults with biopsy-proven, active lupus...

Belimumab is a fully humanized, monoclonal antibody against BlyS/BAFF. Postmarketing studies estimate that approximately 5% of all SLE patients are on treatment with belimumab (Table 1) [Yazdany et al. 2013; Askanase et al. 2014]. The protocol for the phase III clinical trials was adjusted based on the data from phase II trials.

Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. To assess the benefits and harms of belimumab (alone or in combination) in systematic lupus erythematosus.

2 天之前 · Systemic lupus erythematosus (SLE) is an autoimmune disease with unknown etiology. For newly diagnosed SLE, there are few studies analyzing whether the use of belimumab can reduce the dose of glucocorticoids while maintaining disease remission.

Objectives: Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study. Methods: RNA-sequencing was performed in the blood of active SLE …

2013年4月18日 · Effects of Belimumab on Biomarkers of Systemic Lupus Erythematosus (SLE) and on the Immune System.

2020年9月16日 · Current treatment for proliferative lupus nephritis involves intensive immunosuppression, usually with cyclophosphamide or mycophenolate mofetil and high-dose glucocorticoids in a...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020. Benlysta was approved to treat lupus in children in 2019 and lupus nephritis in children in 2022.